Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis  Cori Daines, Donald VanDeVanter,

Slides:



Advertisements
Similar presentations
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
Advertisements

Effect of dornase alfa on inflammation and lung function: Potential role in the early treatment of cystic fibrosis  Michael W. Konstan, Felix Ratjen 
IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis  Donald.
Donald R. VanDevanter, David J. Pasta, Michael W. Konstan 
Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus  Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,
A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation.
Is infection with hypermutable Pseudomonas aeruginosa clinically significant?  Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir 
Sweat conductivity: An accurate diagnostic test for cystic fibrosis?
Zachary M. Sellers, Lori McGlocklin, Andrea Brasch 
Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort  Margaret Rosenfeld, Julia Emerson, Sharon McNamara,
PCR detection of Burkholderia cepacia complex as one of key factors to handle a long- term outbreak  Klara Dedeckova, Libor Fila, Veronika Skalicka, Jana.
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation.
Early rise of anti-Pseudomonas antibodies and a mucoid phenotype of Pseudomonas aeruginosa are risk factors for development of chronic lung infection—A.
The relationship between sweat chloride levels and mortality in cystic fibrosis varies by individual genotype  Julia C. Espel, Hannah L. Palac, Ankit.
Michael Anstead, Sonya L. Heltshe, Umer Khan, Joseph T
Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis  P. Gonçalves.
Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis  M. Proesmans, F. Vermeulen,
Samantha A. Woodruff, Marci K. Sontag, Frank J. Accurso, Ronald J
Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry.
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint  D.R. VanDevanter, A. Yegin, W.J. Morgan,
Laura Viviani, Baroukh M. Assael, Eitan Kerem 
Statistical limitations of percent ideal body weight as measure for nutritional failure in patients with cystic fibrosis  T.O. Hirche, H. Hirche, S. Jungblut,
Early attained weight and length predict growth faltering better than velocity measures in infants with CF  Sonya L. Heltshe, Drucy S. Borowitz, Daniel.
Cirrhosis and other liver disease in cystic fibrosis
Katelyn Krivchenia, Don Hayes, Joseph D. Tobias, Dmitry Tumin 
Rate of improvement of CF life expectancy exceeds that of general population— Observational death registration study  Matthew N. Hurley, Tricia M. McKeever,
Amanda L. Brennan, Khin M. Gyi, David M
Pulmonary exacerbations in CF patients with early lung disease
Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection  Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,
Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study  Christine Rønne.
Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state  Bradley.
Evaluation of salt supplementation in CF infants
Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients  J.L. Fothergill,
Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn 
A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation.
Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis
A.H. Gifford  Journal of Cystic Fibrosis 
Initial evaluation of the Parent Cystic Fibrosis Questionnaire—Revised (CFQ-R) in infants and young children  Adrianne N. Alpern, Lyndia C. Brumback,
Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis  Sanja Stanojevic, Valerie Waters, Joseph L.
Physiologic endpoints for clinical studies for cystic fibrosis
Antonia V. Bennett, Donald L. Patrick, James F. Lymp, Todd C
Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: A reconsideration  Drucy Borowitz, Daniel Gelfond, Karen.
E. Tschiedel, H. Grasemann, F. Ratjen  Journal of Cystic Fibrosis 
Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis  K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,
D.Y.F. Mak, J. Sykes, A.L. Stephenson, L.C. Lands 
Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint  M.W. Konstan, J.S. Wagener, A. Yegin, S.J.
Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.
Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients  Valerie Waters, Eshetu G. Atenafu, Annie.
Segregation of children with CF diagnosed via newborn screening and acquisition of Pseudomonas aeruginosa  Karen O. McKay, Peter J. Cooper, Peter P. van.
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005  F.A. Millar, N.J. Simmonds, M.E. Hodson  Journal.
A new method of sweat testing: the CF Quantum®sweat test
V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume 
Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis  Cori Daines, Donald VanDeVanter,
Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies  Don B. Sanders, Huichuan J. Lai,
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R
Serum-surfactant SP-D correlates inversely to lung function in cystic fibrosis  Hanne Vebert Olesen, Uffe Holmskov, Peter Oluf Schiøtz, Grith Lykke Sørensen 
C. R. Hansen, T. Pressler, K. G. Nielsen, P. Ø. Jensen, T
CFTR modulators and pregnancy: Our work has only just begun
Exercise-induced hypoxemia and cardiac arrhythmia in cystic fibrosis
Brian S. Murphy, Heather M
Michael W. Konstan, Jeffrey S. Wagener, Donald R. VanDevanter, David J
Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub 
David Adeboyeku, Sandra Scott, Margaret E. Hodson 
Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa  C.E. Wainwright, A.L. Quittner, D.E.
Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005  Donald R. VanDevanter, Eric P. Elkin,
Absence of a gender gap in survival
Cystic fibrosis and pregnancy in the modern era: A case control study
R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P
Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience  C.R.
Presentation transcript:

Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis  Cori Daines, Donald VanDeVanter, Umer Khan, Julia Emerson, Sonya Heltshe, Sharon McNamara, Michael Anstead, Markus Langkamp, Gerd Doring, Felix Ratjen, Bonnie Ramsey, Ronald L. Gibson, Wayne Morgan, Margaret Rosenfeld  Journal of Cystic Fibrosis  Volume 13, Issue 5, Pages 542-549 (September 2014) DOI: 10.1016/j.jcf.2014.06.005 Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Serum antibody titers in non-CF control children, children with CF that remained Pa negative for the subsequent year and children with CF that had initial isolation of Pa from a respiratory culture within the subsequent year. Box plots of serum titers of antibodies against Pa alkaline protease (left panel), exotoxin A (center panel), and elastase (right panel). Non-CF control children (hashed bars), children with CF that did not have Pa cultured in the subsequent year after serum collection (clear bars), and children with CF that had Pa cultured within the subsequent 12months, 6months, and concurrently with serum collection (gray bars) are shown. Sample sizes are shown above the bars. Medians, 25th and 75th percentiles and ranges are depicted. Journal of Cystic Fibrosis 2014 13, 542-549DOI: (10.1016/j.jcf.2014.06.005) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Odds ratios for the effect of log10 serum antibody titers on risk of concurrent Pa isolation and Pa isolation within 6months and 12months after serum collection in children with CF. A logistic regression model was adjusted for patient sex and age (1–≤3years, >3–≤6years, >6years). Odds ratios (log scale) are shown for risk of concurrent Pa isolation (clear circles), Pa isolation within 6months after serum collection (gray circles), and within 12months (black circles) after serum collection. Bars represent 95% confidence intervals for odds ratios. Journal of Cystic Fibrosis 2014 13, 542-549DOI: (10.1016/j.jcf.2014.06.005) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 ROC curves for serology as a predictor of subsequent Pa isolation in children with CF. Curves for alkaline protease (left), exotoxin A (center), and elastase (right) prediction of concurrent Pa isolation (black lines), within 6months (gray lines), and within 12months (hashed lines) of serum collection are shown. Antibody titers of 100 (open circles) are noted. Journal of Cystic Fibrosis 2014 13, 542-549DOI: (10.1016/j.jcf.2014.06.005) Copyright © 2014 European Cystic Fibrosis Society. Terms and Conditions